---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-021718"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T07:48:29.357417+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioMarin guides ~$3.2B FY2025 revenue; plans $850M notes + $2.8B loans for Amicus deal

## Summary
- FY2025 preliminary total revenue ~$3.2B, including ~$920M from VOXZOGO; cash & investments ~$2.1B.
- Launches $850M senior notes due 2034 and $2.8B in term loans ($2B Term Loan B + $800M Term Loan A) plus $600M revolver.
- Proceeds escrowed; notes due Dec 2034 subject to special mandatory redemption at 100% if Amicus acquisition fails to close by Dec 19, 2026.
- Acquisition of Amicus expected to close in Q2 2026, subject to Amicus stockholder vote and antitrust clearance.

## SEC filing metadata
- accession: 0001193125-26-021718
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312526021718/0001193125-26-021718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312526021718/d100834d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-021718
- JSON: https://secwatch.observer/filing/0001193125-26-021718.json
- Plain text: https://secwatch.observer/filing/0001193125-26-021718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.